

## LIST OF PUBLICATIONS

- 1: Evangelisti C, Paganelli F, Giuntini G, Mattioli E, Cappellini A, Ramazzotti G, Faenza I, Maltarello MC, Martelli AM, Scotlandi K, **Chiarini F**, Lattanzi G. Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. *Cells*. 2020 Mar 22;9(3):774. doi: 10.3390/cells9030774.
- 2: **Chiarini F**, Paganelli F, Martelli AM, Evangelisti C. The Role Played by Wnt/ $\beta$ -Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. *Int J Mol Sci*. 2020 Feb 7;21(3):1098. doi: 10.3390/ijms21031098.
- 3: Martelli AM, Paganelli F, **Chiarini F**, Evangelisti C, McCubrey JA. The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. *Cancers (Basel)*. 2020 Feb 1;12(2):333. doi: 10.3390/cancers12020333.
- 4: Evangelisti C, **Chiarini F**, Cappellini A, Paganelli F, Fini M, Santi S, Martelli AM, Neri LM, Evangelisti C. Targeting Wnt/ $\beta$ -catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. *J Cell Physiol*. 2020 Jun;235(6):5413-5428. doi: 10.1002/jcp.29429.
- 5: Evangelisti C, **Chiarini F**, Paganelli F, Marmioli S, Martelli AM. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. *Biochim Biophys Acta Mol Cell Res*. 2020 Apr;1867(4):118635. doi: 10.1016/j.bbamcr.2019.118635.
- 6: Mazzotti E, Teti G, Falconi M, **Chiarini F**, Barboni B, Mazzotti A, Muttini A. Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model. *Cells*. 2019 Sep 20;8(10):1116. doi: 10.3390/cells8101116.
- 7: Paganelli F, Lonetti A, Anselmi L, Martelli AM, Evangelisti C, **Chiarini F**. New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. *Adv Biol Regul*. 2019 Dec;74:100649. doi: 10.1016/j.jbior.2019.100649.
- 8: **Chiarini F**, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. *Biochim Biophys Acta Mol Cell Res*. 2019 Aug;1866(8):1322-1337. doi: 10.1016/j.bbamcr.2019.03.013.
- 9: **Chiarini F**, Evangelisti C, Cenni V, Fazio A, Paganelli F, Martelli AM, Lattanzi G. The Cutting Edge: The Role of mTOR Signaling in Laminopathies. *Int J Mol Sci*. 2019 Feb 15;20(4):847. doi: 10.3390/ijms20040847.
- 10: Ramazzotti G, Fiume R, **Chiarini F**, Campana G, Ratti S, Billi AM, Manzoli L, Follo MY, Suh PG, McCubrey J, Cocco L, Faenza I. Phospholipase C- $\beta$ 1 interacts with cyclin E in adipose-derived stem cells osteogenic differentiation. *Adv Biol Regul*. 2019 Jan;71:1-9. doi: 10.1016/j.jbior.2018.11.001. Epub 2018 Nov 5.
- 11: Evangelisti C, **Chiarini F**, McCubrey JA, Martelli AM. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. *Int J Mol Sci*. 2018 Jun 26;19(7):1878. doi: 10.3390/ijms19071878.
- 12: Bertacchini J, Frasson C, **Chiarini F**, D'Avella D, Accordi B, Anselmi L, Barozzi P, Forghieri F, Luppi M, Martelli AM, Basso G, Najmaldin S, Khosravi A, Rahim F, Marmioli S. Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. *Adv Biol Regul*. 2018 May;68:2-9. doi: 10.1016/j.jbior.2018.03.001.
- 13: Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, **Chiarini F**, Evangelisti C, Barata JT, Martelli AM. Therapeutic targeting of CK2 in acute and chronic leukemias. *Leukemia*. 2018 Jan;32(1):1-10. doi: 10.1038/leu.2017.301
- 14: Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, Bertaina A, Locatelli F, Simioni C, Neri LM, **Chiarini F**, Lonetti A, Buontempo F, Orsini E, Pession A, Manzoli L, Martelli AM, Evangelisti C. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. *J Cell Physiol*. 2018 Mar;233(3):1796-1811. doi: 10.1002/jcp.26135.
- 15: Masetti R, Bertuccio SN, Astolfi A, **Chiarini F**, Lonetti A, Indio V, De Luca M, Bandini J, Serravalle S, Franzoni M, Pigazzi M, Martelli AM, Basso G, Locatelli F, Pession A. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. *J Hematol Oncol*. 2017 Jan 21;10(1):26. doi: 10.1186/s13045-017-0396-0.
- 16: Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, **Chiarini F**, Barata JT, Pyne S, Pyne NJ, Martelli AM. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. *Leukemia*. 2016 Nov;30(11):2142-2151. doi: 10.1038/leu.2016.208. Epub 2016 Jul 27.
- 17: Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zamboni L, Neri LM, Martelli AM, **Chiarini F**. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. *J Hematol Oncol*. 2016 Oct 24;9(1):114. doi: 10.1186/s13045-016-0344-4.

- 18: Buontempo F, Orsini E, Lonetti A, Cappellini A, **Chiarini F**, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- $\kappa$ B. *Oncotarget*. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.
- 19: **Chiarini F**, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. *Biochim Biophys Acta*. 2016 Mar;1863(3):449-463. doi: 10.1016/j.bbamcr.2015.08.015.
- 20: Lonetti A, Cappellini A, Spartà AM, **Chiarini F**, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. *Oncotarget*. 2015 Apr 30;6(12):10399-414. doi: 10.18632/oncotarget.3295.
- 21: **Chiarini F**, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. *Trends Pharmacol Sci*. 2015 Feb;36(2):124-35. doi: 10.1016/j.tips.2014.11.004.
- 22: Evangelisti C, Evangelisti C, **Chiarini F**, Lonetti A, Buontempo F, Neri LM, McCubrey JA, Martelli AM. Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. *Biochim Biophys Acta*. 2015 Jan;1853(1):14-26. doi: 10.1016/j.bbamcr.2014.09.023.
- 23: Evangelisti C, Evangelisti C, Teti G, **Chiarini F**, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM. Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. *Oncotarget*. 2014 Sep 15;5(17):7886-901. doi: 10.18632/oncotarget.2318.
- 24: Bavelloni A, Dmitrienko GI, Goodfellow VJ, Ghavami A, Piazzini M, Blalock W, **Chiarini F**, Cocco L, Faenza I. PLC $\beta$ 1a and PLC $\beta$ 1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. *J Cell Physiol*. 2015 Mar;230(3):587-94. doi: 10.1002/jcp.24776.
- 25: Evangelisti C, Evangelisti C, **Chiarini F**, Lonetti A, Buontempo F, Bressanin D, Cappellini A, Orsini E, McCubrey JA, Martelli AM. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). *Int J Oncol*. 2014 Sep;45(3):909-18. doi: 10.3892/ijo.2014.2525. Epub 2014 Jun 26.
- 26: Spartà AM, Bressanin D, **Chiarini F**, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. *Cell Cycle*. 2014;13(14):2237-47. doi: 10.4161/cc.29267. Epub 2014 May 29.
- 27: Martelli AM, Lonetti A, Buontempo F, Ricci F, Tazzari PL, Evangelisti C, Bressanin D, Cappellini A, Orsini E, **Chiarini F**. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. *Adv Biol Regul*. 2014 Sep;56:6-21. doi: 10.1016/j.jbior.2014.04.004.
- 28: Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, **Chiarini F**, Martelli AM, Tonelli R, Pession A. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia. *Oncotarget*. 2014 Jan 15;5(1):120-30. doi: 10.18632/oncotarget.1337.
- 29: Lonetti A, Antunes IL, **Chiarini F**, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Barata JT, Martelli AM. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. *Leukemia*. 2014 Jun;28(6):1196-206. doi: 10.1038/leu.2013.369.
- 30: Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, **Chiarini F**, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. *Leukemia*. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349.
- 31: Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, **Chiarini F**, Lonetti A, Soncin M, Spartà A, McCubrey JA, Martelli AM. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. *Expert Opin Ther Targets*. 2013 Aug;17(8):921-36. doi: 10.1517/14728222.2013.808333.
- 32: Martelli AM, Lonetti A, Amadori S, McCubrey JA, **Chiarini F**. Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. *Cell Cycle*. 2013 Jun 15;12(12):1815-6. doi: 10.4161/cc.25117.
- 33: Poli A, Faenza I, **Chiarini F**, Matteucci A, McCubrey JA, Cocco L. K562 cell proliferation is modulated by PLC $\beta$ 1 through a PKC $\alpha$ -mediated pathway. *Cell Cycle*. 2013 Jun 1;12(11):1713-21. doi: 10.4161/cc.24806.

- 34: McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, **Chiarini F**, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN. Advances in targeting signal transduction pathways. *Oncotarget*. 2012 Dec;3(12):1505-21. doi: 10.18632/oncotarget.802..
- 35: **Chiarini F**, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. *Oncotarget*. 2012 Dec;3(12):1615-28. doi: 10.18632/oncotarget.762.
- 36: McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, **Chiarini F**, Evangelisti C, Cocco L, Martelli AM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659.
- 37: **Chiarini F**, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. *Oncotarget*. 2012 Dec;3(12):1615-28. doi: 10.18632/oncotarget.762.
- 38: **Chiarini F**, Evangelisti C, Buontempo F, Bressanin D, Fini M, Cocco L, Cappellini A, McCubrey JA, Martelli AM. Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias. *Curr Cancer Drug Targets*. 2012 Nov 21.
- 39: Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, **Chiarini F**, Martelli AM, Steelman LS, McCubrey JA. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. *Adv Biol Regul*. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004.
- 40: McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, **Chiarini F**, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*. 2012 Sep;3(9):954-87. doi: 10.18632/oncotarget.652.
- 41: Bressanin D, Evangelisti C, Ricci F, Tabellini G, **Chiarini F**, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. *Oncotarget*. 2012 Aug;3(8):811-23. doi: 10.18632/oncotarget.579.
- 42: Buontempo F, **Chiarini F**, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM. Activity of the selective I $\kappa$ B kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. *Cell Cycle*. 2012 Jul 1;11(13):2467-75. doi: 10.4161/cc.20859.
- 43: Martelli AM, **Chiarini F**, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. *Expert Opin Ther Targets*. 2012 Jul;16(7):729-42. doi: 10.1517/14728222.2012.694869.
- 44: Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, **Chiarini F**, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. *Leukemia*. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136.
- 45: Martelli AM, **Chiarini F**, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. *Oncotarget*. 2012 Apr;3(4):371-94. doi: 10.18632/oncotarget.477.
- 46: Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, **Chiarini F**, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). *Br J Haematol*. 2012 Jan;156(2):205-12. doi: 10.1111/j.1365-2141.2011.08940.x.
- 47: Martelli AM, Tabellini G, Ricci F, Evangelisti C, **Chiarini F**, Bortul R, McCubrey JA, Manzoli FA. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. *Adv Biol Regul*. 2012 Jan;52(1):214-27. doi: 10.1016/j.advenzreg.2011.09.019.
- 48: Grimaldi C, **Chiarini F**, Tabellini G, Ricci F, Tazzari PL, Battistelli M, Falcieri E, Bortul R, Melchionda F, Iacobucci I, Pagliaro P, Martinelli G, Pession A, Barata JT, McCubrey JA, Martelli AM. AMP-dependent kinase/mammalian target of rapamycin complex 1

signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. *Leukemia*. 2012 Jan;26(1):91-100. doi: 10.1038/leu.2011.269.

49: **Chiarini F**, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA, Martelli AM. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. *Cancer Res*. 2010 Oct 15;70(20):8097-107. doi: 10.1158/0008-5472.CAN-10-1814.

50: Evangelisti C, Ricci F, Tazzari P, **Chiarini F**, Battistelli M, Falcieri E, Ognibene A, Pagliaro P, Cocco L, McCubrey JA, Martelli AM. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. *J Cell Physiol*. 2011 Mar;226(3):822-31. doi: 10.1002/jcp.22407.

51: Martelli AM, Evangelisti C, **Chiarini F**, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Version 2. *Oncotarget*. 2010 Jun;1(2):89-103. doi: 10.18632/oncotarget.114.

52: Biagi C, Astolfi A, Masetti R, Serravalle S, Franzoni M, **Chiarini F**, Melchionda F, Pession A. Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. *Leukemia*. 2010 Jun;24(6):1230-3. doi: 10.1038/leu.2010.81. Epub 2010 Apr 29.

53: Martelli AM, Evangelisti C, **Chiarini F**, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. *Biochim Biophys Acta*. 2010 Sep;1803(9):991-1002. doi: 10.1016/j.bbamcr.2010.04.005.

54: Martelli AM, **Chiarini F**, Evangelisti C, Grimaldi C, Ognibene A, Manzoli L, Billi AM, McCubrey JA. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. *Histol Histopathol*. 2010 May;25(5):669-80. doi: 10.14670/HH-25.669.

55: Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, **Chiarini F**, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA. Erucylphosphocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. *Leukemia*. 2010 Apr;24(4):687-98. doi: 10.1038/leu.2010.32.

56: Martelli AM, Evangelisti C, **Chiarini F**, Grimaldi C, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling network in cancer stem cell biology. *Cancers (Basel)*. 2010 Aug 18;2(3):1576-96. doi: 10.3390/cancers2031576.

57: Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, **Chiarini F**, Ramazzotti G, Bacarani M, Martelli AM, Manzoli L, Martinelli G, Cocco L. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Version 2. *Proc Natl Acad Sci U S A*. 2009 Sep 29;106(39):16811-6. doi: 10.1073/pnas.0907109106. Epub 2009 Sep 10.

58: Martelli AM, Evangelisti C, **Chiarini F**, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. *Expert Opin Investig Drugs*. 2009 Sep;18(9):1333-49. doi: 10.1517/14728220903136775.

59: Bregoli L, **Chiarini F**, Gambarelli A, Sighinolfi G, Gatti AM, Santi P, Martelli AM, Cocco L. Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. *Toxicology*. 2009 Aug 3;262(2):121-9. doi: 10.1016/j.tox.2009.05.017.

60: **Chiarini F**, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. *Cancer Res*. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884.

61: Cappellini A, **Chiarini F**, Ognibene A, McCubrey JA, Martelli AM. The cyclin- dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P glycoprotein cleavage: implications for therapy of drug resistant breast cancers. *Cell Cycle*. 2009 May 1;8(9):1421-5. doi: 10.4161/cc.8.9.8323.

62: Fiume R, Ramazzotti G, Teti G, **Chiarini F**, Faenza I, Mazzotti G, Billi AM, Cocco L. Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. *FASEB J*. 2009 Mar;23(3):957-66. doi: 10.1096/fj.08-121244.

63: Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, **Chiarini F**, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Res*. 2008 Nov 15;68(22):9394-403. doi: 10.1158/0008-5472.CAN-08-2815.

- 64: Falà F, Blalock WL, Tazzari PL, Cappellini A, **Chiarini F**, Martinelli G, Tafuri A, McCubrey JA, Cocco L, Martelli AM. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-cell acute lymphoblastic leukemia. *Mol Pharmacol*. 2008 Sep;74(3):884-95. doi: 10.1124/mol.108.047639.
- 65: McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, **Chiarini F**, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. *Adv Enzyme Regul*. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006.
- 66: **Chiarini F**, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. *Leukemia*. 2008 Jun;22(6):1106-16. doi: 10.1038/leu.2008.79.
- 67: Papa V, Tazzari PL, **Chiarini F**, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. *Leukemia*. 2008 Jan;22(1):147-60. doi: 10.1038/sj.leu.2404980.
- 68: Martelli AM, Tazzari PL, Evangelisti C, **Chiarini F**, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. *Curr Med Chem*. 2007;14(19):2009-23. doi: 10.2174/092986707781368423.
- 69: Croci S, Nicoletti G, Landuzzi L, Palladini A, **Chiarini F**, Nanni P, Lollini PL, De Giovanni C. Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. *Oncol Rep*. 2007 Aug;18(2):451-6.
- 70: Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, **Chiarini F**, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. *Cancer Res*. 2007 May 1;67(9):4287-94. doi: 10.1158/0008-5472.CAN-06-4409.